We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Tissue Regenix Group plc (TRX) Ordinary 0.1p

Sell:0.50p Buy:0.52p 0 Change: 0.005p (0.97%)
Market closed Prices as at close on 9 August 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.50p
Buy:0.52p
Change: 0.005p (0.97%)
Market closed Prices as at close on 9 August 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.50p
Buy:0.52p
Change: 0.005p (0.97%)
Market closed Prices as at close on 9 August 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tissue Regenix Group plc is a United Kingdom-based regenerative medical devices company. The Company is focused on the development of regenerative products using its two platform technologies: decellularization (dCELL), which is used to produce allograft (DermaPure) and xenograft (OrthoPure XT) soft tissue products to promote healing and regeneration, and BioRinse, which is a natural bone filler solution verified to be osteoinductive to stimulate and regenerate native bone growth. The Company is engaged in transforming the treatment of patients in surgical applications, including BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology and Cardiac.

Contact details

Address:
Unit 3
Phoenix Court, Lotherton Way, Garforth
LEEDS
LS25 2GY
United Kingdom
Telephone:
+44 (01904) 567609
Website:
https://www.tissueregenix.com/

Important dates

Future events
Interim results 07 September 2022 07/09/22
Past events
Trading Announcement 19 July 2022 19/07/22
AGM 26 April 2022 26/04/22
Final results 15 March 2022 15/03/22
Trading Announcement 27 January 2022 27/01/22
Interim results 08 September 2021 08/09/21

General stock information

EPIC:
TRX
ISIN:
GB00B5SGVL29
Market cap:
£35.88 million
Shares in issue:
7.04 billion
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Daniel Lee
    Chief Executive Officer, Director
  • David Cocke
    Chief Financial Officer, Director
  • Kirsten Lund
    Group Finance Director, Company Secretary
  • Patti Gary
    Vice President - Clinical Affairs
  • Lance Johnson
    VP, Quality and Regulatory, US
  • Gerald Sharpe
    Vice President - Strategic Partnerships
  • Tina Trimble
    VP, Donor Services, US
  • Christine Rowley
    Technical and Operations Director, UK

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.